Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

Since the discovery of the first MDM2 inhibitors, we have gained deeper insights into the cellular roles of MDM2 and p53. In this review, we focus on MDM2 inhibitors that bind to the p53-binding domain of MDM2 and aim to disrupt the binding of MDM2 to p53. We describe the basic mechanism of action o...

Descripción completa

Detalles Bibliográficos
Autores principales: Haronikova, Lucia, Bonczek, Ondrej, Zatloukalova, Pavlina, Kokas-Zavadil, Filip, Kucerikova, Martina, Coates, Philip J., Fahraeus, Robin, Vojtesek, Borivoj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903693/
https://www.ncbi.nlm.nih.gov/pubmed/34911439
http://dx.doi.org/10.1186/s11658-021-00293-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903693/
https://www.ncbi.nlm.nih.gov/pubmed/34911439
http://dx.doi.org/10.1186/s11658-021-00293-6

Ejemplares similares